mRNA-1769

Phase 2Completed
1 views this week 0 watching
0
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smallpox, Mpox

Conditions

Smallpox, Mpox

Trial Timeline

Aug 15, 2023 → Jul 8, 2025

About mRNA-1769

mRNA-1769 is a phase 2 stage product being developed by Moderna for Smallpox, Mpox. The current trial status is completed. This product is registered under clinical trial identifier NCT05995275. Target conditions include Smallpox, Mpox.

What happened to similar drugs?

3 of 8 similar drugs in Smallpox, Mpox were approved

Approved (3) Terminated (0) Active (5)
🔄FD MVA-BNBavarian NordicPhase 3
🔄IMVAMUNE®Bavarian NordicPhase 3
🔄ACAM2000Emergent BioSolutionsPhase 3
Vaccination with ACAM2000Emergent BioSolutionsApproved
🔄tecovirimatSIGA TechnologiesPhase 3
🔄TPOXXSIGA TechnologiesPhase 3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05995275Phase 2Completed

Competing Products

20 competing products in Smallpox, Mpox

See all competitors
ProductCompanyStageHype Score
Smallpox vaccine, LISTER strain, from chick embryo cellsSanofiPhase 2
35
MVA (smallpox vaccine)SanofiPhase 1
21
ACAM3000 MVA VaccineSanofiPhase 1
29
MVA Smallpox vaccine + PlaceboSanofiPhase 2
35
ACAM1000 + vaccinia virus (calf lymph) smallpox vaccine: DryvaxSanofiPhase 2
27
IMVAMUNE (MVA-BN)Bavarian NordicPhase 2
32
MVA-BNBavarian NordicPhase 1
26
IMVAMUNE®Bavarian NordicPhase 2
32
LF formulation of IMVAMUNE® + FD formulation of IMVAMUNE®Bavarian NordicPhase 2
32
IMVAMUNE + IMVAMUNEBavarian NordicPhase 2
32
FD MVA-BNBavarian NordicPhase 3
37
IMVAMUNE®Bavarian NordicPhase 3
37
IMVAMUNE + IMVAMUNEBavarian NordicPhase 2
32
MVA-BN® (IMVAMUNE) + PlaceboBavarian NordicPhase 2
32
Elstree-BNBavarian NordicPhase 1
26
ACAM2000Emergent BioSolutionsPhase 3
30
VIGIVEmergent BioSolutionsPre-clinical
23
ACAM2000® smallpox vaccineEmergent BioSolutionsPre-clinical
16
BrincidofovirEmergent BioSolutionsPhase 1
19
Vaccination with ACAM2000Emergent BioSolutionsApproved
33